Dry Powder Inhaler Is Expected To Top Us$ 1.3 Bn By 2031
– Rising pollution and respiratory diseases is a key factor driving demand for dry powder inhalers at 7.2% CAGR. – Among the product types, capsule-based inhalers will be the fastest-growing segment owing to simplicity and efficiency of their use. – North America is set to dominate market revenue, followed by key countries in Europe such as the U.K. and Germany.
– AstraZeneca – GlaxoSmithKline plc – Vectura Group plc – Boehringer Ingelheim GmbH – Otsuka Pharmaceutical Co. Ltd. – Norton Healthcare – Respira Therapeutics, Inc. – Cheisi – Cipla
“The coronavirus pandemic has given way to several breathing concerns and respiratory issues, along with widespread pollution in certain countries such as India, which is expected to result in increased demand for dry powder inhalers to tackle with respiratory diseases,” says a lead analyst at Fact.MR.